Press Releases August 5, 2026 04:15 PM

KRONOS WORLDWIDE, INC. ANNOUNCES QUARTERLY DIVIDEND

Kronos Worldwide announces a quarterly dividend increase, reinforcing shareholder returns.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
KRO

Kronos Worldwide, Inc., a leading producer of titanium dioxide, declared a regular quarterly dividend of $0.05 per share, payable September 17, 2026, reflecting confidence in their financial health and commitment to returning value to shareholders.

KRONOS WORLDWIDE, INC. ANNOUNCES QUARTERLY DIVIDEND
KRO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The board declared a quarterly dividend of $0.05 per share.
  • Dividend payable on September 17, 2026, to shareholders of record September 3, 2026.
  • Kronos Worldwide is a major international titanium dioxide producer impacting the chemicals and industrial materials sectors.

DALLAS, TEXAS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kronos Worldwide, Inc. (NYSE:  KRO) announced that its board of directors has declared a regular quarterly dividend of five cents ($0.05) per share on its common stock, payable on September 17, 2026 to stockholders of record at the close of business on September 3, 2026.

Kronos Worldwide, Inc. is a major international producer of titanium dioxide products.

* * * * *

Investor Relations Contact

Bryan A. Hanley
Senior Vice President and Treasurer
Tel. 972-233-1700


Risks

  • Dividend depends on company’s ongoing profitability and cash flow, which can be affected by market demand for titanium dioxide.
  • Price volatility in raw materials or regulatory changes in chemical manufacturing could impact financial stability.
  • Global economic conditions and competition in the chemical sector may affect future dividend payments.

More from Press Releases

BCB Bancorp, Inc. Announces Pricing of Common Stock Offering Sep 16, 2026 Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling Sep 16, 2026 Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) Sep 16, 2026 XTEND Selected as Gauntlet II Top Performer in $1 Billion U.S. Drone Dominance Program Sep 16, 2026 CVB Financial Corp. Announces 148th Consecutive Quarterly Cash Dividend Sep 16, 2026